246 related articles for article (PubMed ID: 24892263)
1. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gatza E; Braun T; Levine JE; Ferrara JL; Zhao S; Wang T; Chang L; Harris A; Pawarode A; Kitko C; Magenau JM; Yanik GA; Couriel DR; Goldstein S; Connelly J; Reddy P; Paczesny S; Choi SW
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1426-34. PubMed ID: 24892263
[TBL] [Abstract][Full Text] [Related]
2. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
Levine JE; Paczesny S; Mineishi S; Braun T; Choi SW; Hutchinson RJ; Jones D; Khaled Y; Kitko CL; Bickley D; Krijanovski O; Reddy P; Yanik G; Ferrara JL
Blood; 2008 Feb; 111(4):2470-5. PubMed ID: 18042798
[TBL] [Abstract][Full Text] [Related]
3. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
[TBL] [Abstract][Full Text] [Related]
4. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
[TBL] [Abstract][Full Text] [Related]
6. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
9. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.
Choi SW; Stiff P; Cooke K; Ferrara JL; Braun T; Kitko C; Reddy P; Yanik G; Mineishi S; Paczesny S; Hanauer D; Pawarode A; Peres E; Rodriguez T; Smith S; Levine JE
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1525-32. PubMed ID: 22469883
[TBL] [Abstract][Full Text] [Related]
10. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
[TBL] [Abstract][Full Text] [Related]
11. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
Choi SW; Braun T; Henig I; Gatza E; Magenau J; Parkin B; Pawarode A; Riwes M; Yanik G; Dinarello CA; Reddy P
Blood; 2017 Oct; 130(15):1760-1767. PubMed ID: 28784598
[TBL] [Abstract][Full Text] [Related]
15. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
Yanik GA; Ho VT; Levine JE; White ES; Braun T; Antin JH; Whitfield J; Custer J; Jones D; Ferrara JL; Cooke KR
Blood; 2008 Oct; 112(8):3073-81. PubMed ID: 18664626
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.
Yanik GA; Horowitz MM; Weisdorf DJ; Logan BR; Ho VT; Soiffer RJ; Carter SL; Wu J; Wingard JR; Difronzo NL; Ferrara JL; Giralt S; Madtes DK; Drexler R; White ES; Cooke KR
Biol Blood Marrow Transplant; 2014 Jun; 20(6):858-64. PubMed ID: 24607553
[TBL] [Abstract][Full Text] [Related]
17. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
18. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
19. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
Xhaard A; Hermet E; Bay JO; Peffault de Latour R
Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
